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Both acute and chronic graft-versus-host disease (GVHD) are major causes of morbidity and mortality in
patients undergoing allogeneic hematopoietic stem cell transplantation (AHSCT). The optimal pharmaco-
logical regimen for GVHD prophylaxis is unclear, but combinations of a calcineurin inhibitor (cyclosporin or
tacrolimus [Tac]) and an antimetabolite (methotrexate or mycophenolate mofetil [MMF]) are typically used.
We retrospectively evaluated the clinical outcomes of 414 consecutive patients who underwent AHSCT from
sibling (SD) or unrelated donors (UD) with Tac/MMF combination, between January 2005 and August 2010.
The median follow-up was 60 months. Less than one third of the patients received a reduced-intensity
chemoregimen. The incidence of grades III and IV acute GVHD was 22.3% and 36.5% in SD and UD groups,
respectively (P ¼ .0007). The incidence of chronic GVHD was 47.1% and 52.7% in the SD and UD groups,
respectively. Nonrelapse mortality (NRM) at 60 months was 33.3% and 46.5% in the SD and UD groups,
respectively (P ¼ .0016). The incidence of relapse was 22.4% for UD and 28.8% for SD. Five-year overall survival
was 43% and 34% in the SD and UD groups, respectively (P ¼ .0183). GVHD was the leading cause of death for
the entire cohort. Multivariable analysis showed that 8/8 HLA match, patient’s age < 60, and low-risk disease
were associated with better survival. The use of Tac/MMF for GVHD prophylaxis was associated with a
relatively high incidence of severe acute GVHD and NRM in AHSCT from sibling and unrelated donors.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Graft-versus-host disease (GVHD) continues to be a major
cause of morbidity and mortality after allogeneic hemato-
poietic stem cell transplantation (AHSCT) [1-4]. Methods to
prevent GVHD in most centers consist of a combination of
methotrexate (MTX) and a calcineurin inhibitor, either
cyclosporine A (CSA) or tacrolimus (Tac). Despite the use of
pharmacological GVHD prophylaxis, the rate of grade II to IV
acute GVHD (aGVHD) ranges from 35% to 50% in trans-
plantations from HLA-matched sibling donors (SD) and up to
70% in transplantations from unrelated donors (UD) [3,5,6].
Therefore, there is a need for safer and more effective GVHD
preventive regimens, aimed at improving overall trans-
plantation outcomes.
Mycophenolate mofetil (MMF) is a prodrug of the im-
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for the guanine monophosphate pathway needed for T and B
lymphocyte proliferation [7]. Storb et al. initially, showed
evidence of synergy between CSA and MMF in preventing
GVHD when tested in dog models [8]. Clinical trials with a
CSA/MMF combination resulted in an incidence of aGVHD
grade II to IV of 42% to 63% in the context of various intensity
conditioning regimens and donor types [9-15]. In a small
retrospective cohort of nonmyeloablative transplantations,
Le Blanc et al. ﬁrst reported increased rates of aGVHD when
MMF was used instead MTX in combination with CSA for
aGVHD prophylaxis [16].
Three prospective trials studied the combination of MMF
with Tac after reduced-intensity conditioning and docu-
mented rates of grade II to IV aGVHD up to 15% in SD and 54%
in UD [17-19]. However, a randomized phase II trial found
that the Tac/MMF combination resulted in a high incidence
of grades III to IV aGVHDwhen compared with Tac/MTX (19%
versus 4%, P ¼ .03) after a full-intensity preparative regimen
[20]. Multiple centers adopted Tac/MMF as the standard
GVHD prophylactic regimen, given the advantages of earlier
engraftment and less mucositis. Given the heterogeneity ofTransplantation.
Table 1
Patient Characteristics
Unrelated
Transplantations
Matched Related
Transplantations
P Value
No. of patients 203 211
Patient age,
median (range)
44.5 (18-69) 48 (23-71) .0233
Disease .2132
AML 80 (39%) 75 (36%)
MDS 21 (10%) 26 (12%)
ALL 30 (15%) 19 (9%)
NHL 32 (16%) 46 (22%)
Other* 40 (20%) 45 (21%)
Conditioning .4541
Bu/ﬂu 70 (34%) 61 (29%)
Bu/ﬂu/TBIþ 38þ(2) (20%) 43þ(1) (21%)
Flu/mel/TBIþ 11þ(3) (7%) 13þ(5) (9%)
Rþ/ BEAM 19 (9%) 30 (14%)
Othery 60 (30%) 58 (27%)
Donor/recipient sex .0016
F/f 33 (16%) 48 (23%)
F/m 35 (17%) 55 (26%)
M/f 58 (29%) 42 (20%)
M/m 77 (38%) 66 (31%)
Donor/recipient CMV status .1952
Neg/neg 62 (31%) 69 (33%)
Neg/pos 65 (32%) 48 (23%)
Pos/neg 22 (11%) 28 (13%)
Pos/pos 54 (27%) 66 (31%)
Donor age,
median (range)
36.5 (18-60) 46.5 (18-75) <.0001
CD 34þmedian
(range), 106/kg
7.28 (1.49-19.12) 5.78 (2.12-14.05) <.0001
HLA match <.0001
8/8 136 (67%) 194 (92%)
7/8 67 (33%) 17 (8%)
Disease risk .3217
Low 75 (37%) 88 (42%)
High 128 (63%) 123 (58%)
Stem cell source .4960z
PBSC 198 (98%) 208 (99%)
BM 5 (2%) 3 (1%)
No. of prior transplantations .0521
0 193 (95%) 190 (90%)
1 or more (auto) 10 (5%) 21 (10%)
AML indicates acute myelogenous leukemia; MDS, myelodysplastic syn-
drome; NHL, non-Hodgkin lymphoma; ALL, acute lymphoblastic leukemia;
M, male; F, female; Bu, busulfan; mel, melphalan; BEAM, carmustine,
etoposide, cytarabine and melphalan; TBI, total body irradiation; PBSC,
peripheral blood stem cells; BM, bone marrow.
* Other includes chronic myelogenous leukemia, MPD, multiple
myeloma, chronic lymphatic leukemia, PLL, and Hodgkin disease.
y Other includes VP16/TBI, CY/TBI, BAC, CY/FLU/TBI, CVBþ(R), and BU/CY.
z Fisher exact test. The others were chi-square test for the categorical
variables.
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evaluate the efﬁcacy of Tac/MMF regimen in a relatively large
cohort of patients with a long follow-up period. Our objec-
tives were to evaluate the cumulative incidence and severity
of aGHVD, chronic GVHD (cGVDH), nonrelapse mortality
(NRM), relapse, and overall survival (OS) in these patients.
Additionally we aimed to test, in a multivariable model,
donor, recipient, and regimen-related factors for association
with aGVHD, cGVHD, and survival. We found that Tac/MMF
was associated with a high incidence of grades III to IV
aGVHD and high NRM.
METHODS
We retrospectively evaluated all consecutive patients who underwent
AHSCT at Karmanos Cancer Center between Jan 2005 and August 2010 and
received Tac/MMF for GVHD prophylaxis. This study was approved by the
Wayne State University Institutional Review Board. We accessed our
transplantation center database (including patient characteristics, GVHD
grading, and transplantation outcomes), which was prospectively collected
for the Center for International Blood and Marrow Transplant Research
database. Two transplantation physicians reviewed every patient’s medical
record to check and validate GVHD grading and cause of death. The
distinction between acute and chronic GVHD was based on clinical mani-
festations rather than time of onset after transplantation [21]. The primary
endpoint of this study was to evaluate the cumulative incidence (incidence)
and severity of aGVHD based on the consensus grading scale [22]. Secondary
endpoints included incidence and severity of cGVHD using National In-
stitutes of Health consensus [21], incidence of bronchiolitis obliterans,
incidence of cytomegalovirus (CMV) infection, incidence of NRM, incidence
of relapse, OS, progression-free survival (PFS), causes of death, and multi-
variable analysis of possible predictors of aGVHD, cGVHD, and survival.
Inclusion criteria were the following: all adult patients with a diagnosis
of hematologic malignancies including myelodysplastic syndromes and
myeloproliferative disorders were included in the study. Patients had a
suitable HLA 8/8 (A, B, C, and DR) or 7/8 matched SD or UD based on high-
resolution molecular typing. Based on our institutional guidelines, patients
were required to have adequate organ function for AHSCT, including
creatinine clearance of  50 mL/minute, left ventricular ejection fraction
 50%, and pulmonary function values (forced vital capacity, forced expi-
ratory volume in 1 second, and diffusion capacity of the lung for carbon
monoxide) more than  50% predicted.
Excluded from the analysis were patients who underwent AHSCT for
aplastic anemia, patients who had stem cells from cord blood or a hap-
loidentical donor, and patients who received thymoglobulin as part of the
preparative regimen or for GVHD prophylaxis. For patients who underwent
more than 1 AHSCT, we used data from the ﬁrst transplantation only.
Disease Diagnosis and Risk Deﬁnitions
Diseases at high risk for relapse and death after transplantation were
deﬁned primarily based on the Center for International Blood and Marrow
Transplant Research criteria, with a few additions based on published
literature as detailed and published before [23].
Preparative Regimens
Choice of preparative regimen was assigned according to disease diag-
nosis, disease status, age, and comorbidities, and at the discretion of the
treating physician. The description of various high- and reduced-intensity
conditioning regimens were detailed in a previous publications [23-25].
GVHD Prophylaxis
Tac was started at day -3 intravenously (.03 mg/kg/day) and was con-
verted to oral form (approximately 3 to 4 times the intravenous dose) after
the patient demonstrated adequate oral intake after engraftment. Tac dose
was adjusted thrice weekly until day þ30 to achieve trough blood levels of
10 to 15 nmol/L; tapering started at dayþ60 to be discontinued by dayþ180
in the absence of GVHD. MMF was initiated at 10 mg/kg (based on adjusted
weight) orally every 8 hours starting day 3, and then on day þ1, it was
changed to intravenous MMF at 10 mg/kg (based on adjusted weight),
infused every 8 hours. After engraftment, MMF was switched to oral (same
schedule) whenever patients demonstrated adequate oral intake. Each MMF
dosewas rounded to 250mg, 500mg, 750mg, or 1000mg and discontinued
without tapering on day þ30.
Supportive Care
All peripheral blood stem cell donors weremobilized as per the National
Marrow Donor Program standards. All recipients received granulocytecolonyestimulating factor 5 mg/kg starting at day þ6 until engraftment. The
details of supportive care are mentioned elsewhere [23].
Statistical Analysis
Descriptive analyses for baseline characteristics were performed. The
continuous variables were tested with Wilcoxon rank-sum test between the
2 cohorts. The categorical variables were tested with the chi-square test.
When the frequency count was small, the Fisher exact test was used. Inci-
dence rates of infections were estimated using proportions and Wilson’s
95% conﬁdence interval. We calculated the cumulative incidence (incidence)
for acute and chronic GVHD, with disease relapse or death without GVHD as
competing risks. Competing risk for relapse incidence was NRM, for CMV
incidence was death, and for NRM incidence was relapse. The Gray’s test P
values are not signiﬁcant unless otherwise mentioned. The incidence of
aGVHD or cGVHD was calculated with disease relapse or death without
GVHD as competing risks. For calculating the incidence of grade III or IV
aGVHD, disease relapse or death without aGVHD were counted as
competing risks, and all lower grade aGVHD events were ignored. The
Kaplan-Meier estimator was used to calculate PFS (deﬁned as the time from
transplantation to relapse or progression or death from any cause) and OS
Figure 1. The cumulative incidence of (A) grade II to IV aGVHD and (B) grade III-IV aGVHD.
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alive without relapse were censored at the date of last follow-up, which was
July 31, 2012. Cox regression models adjusted for various prognostic factors
were used for GVHD (both acute and chronic) and OS. We evaluated the
association between pretransplantation factors (donor type, age, sex, HLA
mismatch, preparative regimen) and GVHD (both acute and chronic).
Furthermore, we evaluated the association between pretransplantation
factors (donor type, HLA mismatch, CMV status, disease risk, patient age)
and survival. All P values are 2-sided and not adjusted for multiple testing
due to the nature of this exploratory study.RESULTS
Patient Characteristics
Table 1 summarizes the baseline characteristics of pa-
tients who received Tac/MMF for GVHD prophylaxis. Two
hundred and eleven patients underwent transplantation
from SD, whereas 203 underwent transplantation from UD.
The median age of patients was 48 years (range, 23 to 71) in
the SD group and 44.5 years (range, 18 to 69) in the UD group
(P ¼ .023). The median age of donors was 46.5 years (range,
18 to 75) for the SD and 36.5 years (range,18 to 60) for the UDFigure 2. The cumulative incidence of cGVHD.(P < .0001). There were more HLA-mismatched trans-
plantations in the UD group compared with in the SD group;
33% versus 8% (P< .0001). There were more female donors in
the SD group (49%) compared with the UD group (33%) (P ¼
.0016). The median number of CD34þ stem cells infused was
5.78 106/kg (range, 2.12 to 14.05) and 7.28 106/kg (range,
1.49 to 19.12) of recipient weight for the SD and UD groups,
respectively (P< .0001). All patients engrafted at a median of
day 11. Three patients in UD group died of graft failure.Graft-Versus-Host Disease
The incidence of grades II to IV aGVHD was 47.4% (95%
conﬁdence interval [CI] 40% to 54%) and 55.2% (95% CI, 48% to
61%) in SD and UD groups, respectively (Figure 1A). The
incidence of severe aGVHD (grades III to IV) was 22.3% (95%
CI, 16% to 28%) in the SD group versus 36.5% (95% CI, 29% to
43%) in the UD group (P¼ .0007) (Figure 1B). The incidence of
cGVHD at 24 months was 47.1% (95% CI, 40% to 53%) and
52.7% (95% CI, 45% to 59%) in SD and UD groups, respectivelyFigure 3. The cumulative incidence of nonrelapse mortality.
Figure 4. The cumulative incidence of relapse.
Figure 5. Overall survival.
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24 months was 27.6% (95% CI, 22% to 34%) and 26.1% (95% CI,
20% to 32%) in SD and UD groups, respectively. The incidence
of bronchiolitis obliterans at 60monthswas 14.0% (95% CI, 9%
to 19%) and 11.6% (95% CI, 7% to 16%) in SD and UD groups,
respectively.Infections, NRM, and Cause of Death
The incidence of CMV reactivation was 27.2% (95% CI, 21%
to 33%) and 23.2% (95% CI, 18% to 29%) in SD and UD groups,
respectively. The incidence of NRM at 60 months was 33.3%
(95% CI, 27% to 40%) versus 46.5% (95% CI, 39% to 53%) for the
SD and UD groups, respectively (P ¼ .0016), as shown in
Figure 3. Only 15% of patients with a history of grade III to IV
aGVHD were alive by the last date of follow-up.Relapse, Survival and Causes of Death
The incidence of relapse was 28.8% (95% CI, 23% to 35%)
and 22.4% (95% CI, 17% to 29%) in SD and UD groups,
respectively (Figure 4). The causes of death are shown in
Table 2. The main cause of death was GVHD, followed by
relapse in both groups. With a median follow-up of
60 months (95% CI, 54 to 64), the 5-year OS was 43% (95% CI,
34% to 51%) and 34% (95% CI, 27% to 41%) in SD and UDTable 2
Causes of Death
Causes of Death Related Unrelated Total
No. of deaths 115 (55%) 133 (66%) 248 (60%)
GVHD 56 (49%) 76 (57%) 132 (53%)
Relapse/progression 48 (42%) 39 (29%) 87 (35%)
Sepsis 3 (3%) 9 (7%) 12 (5%)
MOF 3 (3%) 5 (4%) 8 (3%)
Graft failure 0 3 (2%) 3 (1%)
DAH 2 (2%) 0 2 (1%)
Secondary malignancy 3 (3%) 1 (1%) 4 (2%)
GVHD indicates graft-versus-host disease; MOF, multiorgan failure; DAH,
diffuse alveolar hemorrhage.
Data presented are n (%).groups, respectively (log-rank P ¼ .0183) (Figure 5). Median
survival was 40.3 months (95% CI, 15 to 73 months) for re-
cipients of allografts from SD and 15.1 months (95% CI, 11 to
26 months) for recipients of allografts from UD.
Factors Associated with GVHD and Survival
Cox’s multivariable analysis showed that transplantations
from donors HLA-matched at 7/8 antigens and UD were
associated with higher risk for aGVHD (P < .0001 and P <
.014, respectively), as shown in Table 3. Furthermore, trans-
plantation from UD, older donors (>30 years), and the use of
total body irradiation were associated with higher risk for
cGVHD (P < .0001, P ¼ .011, and P ¼ .040, respectively)
(Table 4). Patient age (<60 years), low risk for relapse/death,
and absence of an HLAmismatchwere associatedwith better
overall survival (P < .0001, P < .0001, and P ¼ .003, respec-
tively, as shown in Table 5).
DISCUSSION
We report on the GVHD and survival outcomes in a cohort
of AHSCT patients treated with a uniform GVHD prophylaxis
regimen of Tac/MMF. To our knowledge, this is the largest
published cohort of patients (N ¼ 414) with the longest
follow-up (median of 60 months). We observed a relatively
high incidence of severe aGVHD (grade III to IV) in both the
SD and UD groups (22.3% and 36.5%, respectively) with high
NRM (32.5% and 46.5% at 5 years, respectively). These rates of
grade III to IV aGVHD are higher than previously published
randomized GVHD prevention trials using calcineurin in-
hibitors and MTX, as well as single arm phase II trials using
Tac/MMF (Tables 6 and 7) [5,6,17-20,26-28]. Large proportion
of patients in our cohort received high-intensity preparative
regimens as well as transplantations from HLA-mismatchedTable 3
Cox’s Multivariable Models for Time to aGVHD*
Parameter Category P Value HR 95% CI
HLA match Mismatch <.0001 2.320 1.708-3.151
Donor type UD .014 1.479 1.084-2.018
Conditioning regimen High intensity .4885 .905 .684-1.199
Donor age, yr >45 .0661 1.420 .977-2.065
Donor age, yr 31-45 .4416 1.137 .820-1.575
Donor sex Female .3886 1.119 .867-1.444
TBI With TBI .4503 1.167 .781-1.744
aGVHD indicates acute graft-versus-host disease; HR, hazard ratio;
CI, conﬁdence interval; TBI, total body irradiation; UD, unrelated donor.
* All grades of GVHD.
Table 4
Cox’s Multivariable Models for Time to cGVHD*
Parameter Category P Value HR 95% CI
Ag mismatch Mismatch .4990 .873 .588-1.295
Donor type UD .0001 1.975 1.388-2.810
Conditioning regimen High intensity .0771 1.327 .970-1.816
Donor age > 45 .0654 1.492 .975-2.285
Donor age 31-45 .011 1.569 1.103-2.230
Donor sex Female .2287 1.188 .897-1.573
TBI With TBI .040 .623 .398-.975
cGVHD indicates chronic graft-versus-host disease; HR, hazard ratio; CI,
conﬁdence interval; ag, antigen; TBI, total body irradiation; UD, unrelated
donor.
* All grades of GVHD.
Table 5
Cox’s Multivariable Models for OS
Parameter Category P Value HR 95% CI
Patient age, yr >60 <.0001 1.973 1.455-2.675
Relapse risk High <.0001 1.786 1.361-2.342
HLA match Mismatch .0033 1.579 1.164-2.143
D/r (/þ) CMV Yes .6028 1.077 .815-1.424
Donor type UD .2210 1.183 .904-1.550
OS indicates overall survival; D/r, donor/recipient; CMV, cytomegalovirus;
UD, unrelated donor; HR, hazard ratio; CI, conﬁdence interval.
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higher risk of GVHD [4,13,14].
It is not clear if the use of Tac/MMF combination for GVHD
prophylaxis has beenmaximally optimized. Wakahashi et al.,
in a small retrospective study of AHSCT from UD, showed
that patients with measured MMF area under the curve of
> 30 mg hour/mL had no grade II to IV aGVHD or extensive
cGVHD [29]. Recently, McDermott et al. evaluated the asso-
ciation of MMF pharmacokinetics and transplantation out-
comes in a large retrospective report of patients (n ¼ 308)
who underwent transplantation from SD and UD with a
reduced-intensity conditioning regimen. In patients who
underwent transplantation from UD donors, a low myco-
phenolic acid level (steady state) was associated with
increased grade III to IV aGVHD and NRM [30]. Furthermore,
in a small retrospective study, Nishikawa et al. showed that
extended duration of exposure to MMF was associated with
less grade II to IV aGVHD, compared with patients who
stopped MMF at dayþ30 after transplantation [31]. Whether
these maneuvers can improve the future efﬁcacy of this
GVHD prevention regimen remains to be evaluated.
One potential limitation in our study is its retrospective
nature and inherent constraints associated with this type of
analysis. However, only 15% of patients who developed grade
III to IV aGVHD in this series are long-term survivors, which
is similar to the survival rates published before for patients
with grade III to IV aGVHD [32,33]. Another unique aspect of
our cohort is the use of post-transplantation granulocyte
colonyestimulating factor, which has been suspected inTable 6
Randomized GVHD Prevention Trials with Calcineurin Inhibitor and Methotrexate
Study aGVHD Prophylaxis Intensity No. of
Patients
Graft
Type
Ratanatharathorn
1998 Ph III
CSA/MTX versus Tac/MTX Full 329 BM
Nash 2000 Ph III CSA/MTX versus Tac/MTX Full 180 BM
Finke 2009 Ph III CSA/MTX- /þ ATGF Full 202 PBSC
Perkins 2010 Ph II Tac/MTX versus Tac/MMF Full 89 PBSC
Pidala 2012 Ph II Tac/MTX versus Tac/Siro Full 97 PBSC
Cutler 2012 Ph III Tac/MTX versus Tac/Siro Full 304 PBSC
Tac indicates tacrolimus; GVHD, graft-versus-host disease; aGVHD, acute GVHD; BM
sibling donor; NA, not available; CSA, cyclosporine A; MTX, methotrexate; MMF, m
* Estimated from the curve or from the tables.
y About 18% of the patients had at least 1 antigen mismatch. Also HLA C typing
z HLA C mismatch in 14% to 20% of patients.
x HLA 9/10 or 10/10 matched donors were included (the author did not specify
k Statistically signiﬁcant.
{ At unknown duration of follow-up.
# Moderate or severe cGVHD.some retrospective studies to increase aGVHD rates when
used after bone marrow grafts but not after peripheral blood
stem cell grafts [34-41].
In addition to the high incidence of severe aGVHD, we
observed a parallel high NRM in our cohort of patients
compared with previous trials. Considering, the long follow-
up for our cohort, we observed progressive NRM with no
plateau at 5 years, possibly reﬂecting the long-term impact of
cGVHD. This observation highlights the need for long term
follow-up to fully evaluate transplantation outcomes for
these patients.
Multivariate analysis showed that transplantation from
an HLA-mismatched and UD was associated with higher
risk of aGVHD, whereas the use of UD, total body irradia-
tion, and older donors were associated with higher risk of
cGVHD, in agreement with previous literature [42-48]. In
contrast with previous reports, regimen intensity and donor
sex (female donors) were not shown to be predictive of
GVHD outcomes in our cohort [43-45,47]. Finally, patient’s
age < 60, transplantation from an HLA-matched donor, and
low-risk disease were associated with better overall sur-
vival [4,43,44,49,50].
In summary, the use of the Tac/MMF combination as
pharmacological prophylaxis was associated with high inci-
dence of severe aGVHD and NRM, especially after trans-
plantations from UD. Alternative GVHD prevention regimens
are needed to improve AHSCT outcomes. New GVHD pre-
vention agents and regimens are showing some promise in
lowering GVHD rates [23,51,52]. Phase III randomized trials
(with long-term follow-up) are needed to prove the efﬁcacy
of these regimens in preventing GVHD and improving
survival.Graft
Source
HLA
Match
aGVHD III-IV, % cGVHD at 2 yr, % NRM at 2 yr, %
SD 6/6 17 versus 13 49 versus 55 28 versus 35*
UD 6/6y 25 versus 17 70 versus 76 33 versus 42
UD 10/10z 24 versus 11 58 versus 30 28 versus 19
Mixed 10/10x 4 versus 19k 56 versus 58*,# 30 versus 32*
Mixed 8/8 11 versus 14 64 versus 24k
at 30 m
8 versus 28k
SD 6/6 15 versus 8k 43 versus 54k,{ NA
, bone marrow; PBSC, peripheral blood stem cells; UD, unrelated donor; SD,
ycophenolate mofetil; Siro, sirolimus; ATGF, ATG fresenius.
was not done.
the percentage of mismatched donors).
Table 7
Phase II GVHD Prevention Trials with Tacrolimus and Mycophenolate Mofetil
Study aGVHD Prophylaxis, n Preparative Regimen Graft Type Graft Source HLA Match aGVHD III-IV cGVHD NRM* Median Follow-up
Nieto 2006 32 Flu/TBI 200 PBSC SD 6/6 3% 41%y 15% 19 mo
Sabry 2009 131 Flu/Cy PBSC SD 6/6 .2%z,x 76%y 15% 32 mo
Zohren 2010 50 Flu/TBI 200 PBSC UD 10/10k 16% 61% 26% 37 mo
GVHD indicates graft-versus-host disease; Flu, ﬂudarabine; TBI, total body irradiation; Cy, cyclophosphamide; PBSC, peripheral blood stem cells; SD, sibling
donor; UD, unrelated donor; NRM, nonrelapse mortality.
* At the median follow up.
y Extensive cGVHD.
z Additional 12% developed overlap syndrome with no grade severity mentioned.
x Estimated from the curve or from the tables.
k Six patients had a donor with one antigen mismatch, while one had a donor with 2 antigen mismatches.
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